AI Article Synopsis
- A study analyzed the effects of high-dose cytarabine (HD-AraC) on acute myeloid leukemia (AML) patients before they received allogeneic stem cell transplants.
- Results showed that patients treated with HD-AraC had better outcomes in disease-free survival (DFS), overall survival (OS), and lower relapse rates compared to those who did not receive it.
- Specifically, patients treated with HD-AraC showed 4-year DFS of 79% versus 49%, OS of 82% versus 56%, and a cumulative incidence of relapse of 18% versus 42%.
Article Abstract
Benefit of high-dose cytarabine (HD-AraC) for acute myeloid leukemia (AML) prior to allogeneic hematopoietic stem cell transplantation (allo-HSCT) remains unknown. We retrospectively analyzed data from 79 non-core-binding-factor AML patients who underwent allo-HSCT in their first complete remission (CR1). In univariate analysis, HD-AraC (≥4 g/m/day) before allo-HSCT improved disease-free survival (DFS) ( = .018), overall survival (OS) ( = .029), and cumulative incidence of relapse (CIR) ( = .033). Four-year DFS, OS, and CIR of patients receiving and not receiving HD-AraC were 79% vs. 49%, 82% vs. 56%, and 18% vs. 42%, respectively. In multivariate analysis, HD-AraC was a positive prognostic factor for DFS (hazard ratio (HR) = 0.36, 95% confidence interval (CI): 0.14-0.88), OS (HR = 0.37, 95% CI: 0.14-0.99), and CIR (HR = 0.38, 95% CI; 0.14-1.0). Our study demonstrates that HD-AraC before allo-HSCT at a dose ≥4 g/m/day is effective for treating AML patients in CR1.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1080/10428194.2020.1805112 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
De-escalated Induction Therapy and Thiotepa/Busulfan-based Autologous Stem Cell Transplantation for Primary Central Nervous System Lymphoma.
Clin Lymphoma Myeloma Leuk
December 2024
Tom Baker Cancer Centre and University of Calgary, Calgary, Canada.
Background: Thiotepa-based autologous stem cell transplantation (ASCT) improves survival in primary central nervous system lymphoma (PCNSL), but > 30% of patients are unable to undergo ASCT following commonly used intensive induction regimens.
Methods: This retrospective population-based study included consecutive patients ≥ 18 years old with PCNSL who were intended for ASCT in Alberta, Canada between 2011 and 2022. A reduced-intensity induction protocol was further abbreviated in 2018 to decrease toxicity and expediate ASCT by incorporating rituximab, procarbazine, and only 2 doses of high-dose methotrexate and 1 cycle of high-dose cytarabine before consolidation with thiotepa-busulfan conditioning.
Efficacy of Midostaurin Combined With Intensive Chemotherapy in Core Binding Factor Leukemia: A Phase II Clinical Trial.
Am J Hematol
December 2024
Department of Health Sciences, University of Milan, Milan, Italy.
Samples from 34 adult patients newly diagnosed with core binding factor leukemia (CBFL) were collected both at the time of diagnosis and at relapse and were centrally analyzed. Eligible patients received either standard induction CT known as "3 + 7" or an equivalent regimen, according to the recruiting center's policy. Patients who achieved CR or CRi received 3 courses of high-dose ARA-C (Cytarabine) 3000 mg/m every 12 h on days 1, 3, and 5, along with midostaurin at the dose of 50 mg b.
View Article and Find Full Text PDFAcute myeloid leukemia management and research in 2025.
CA Cancer J Clin
December 2024
Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Article Synopsis
Therapy-related hand-foot syndrome: a review.
J Chemother
December 2024
Department of Medical Oncology, Amrita Institute of Medical Sciences, Amrita Vishwa Vidyapeetham, Kochi, India.
Article Synopsis
Mitoxantrone-Based Novel Conditioning Regimen Leads to Great Survival Benefit in Peripheral T-Cell Lymphoma Compared to BEAM Regimen.
Cancer Med
December 2024
Department of Hematology, Huadong Hospital, Fudan University, Shanghai, China.
Background: Peripheral T-cell lymphomas (PTCL) frequently result in relapsed or refractory diseases. Upfront autologous hematopoietic stem cell transplantation (ASCT) using the BEAM (carmustine, etoposide, cytarabine, and melphalan) regimen is recommended. However, relapses are common in PTCL, highlighting a critical need for improved survival outcomes in these patients.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!